Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. GAS-FOVEAL CONTACT: A New Approach to Evaluating Positioning Regimens in Macular Hole Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SCLERAL PITS IN CHOROIDEREMIA: Implications for Retinal Gene Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reply to reply ( NONSUPINE POSITIONING IN MACULAR HOLE SURGERY: A Noninferiority Randomized Clinical Trial.)

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. GUNN'S DOTS IN RETINAL IMAGES OF 2,286 ADOLESCENTS: Prevalence, Retinal Distribution and Associations

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Correspondence : CONSTRUCT AND FACE VALIDITY OF THE EYESI INDIRECT OPHTHALMOSCOPE SIMULATOR. [Retina. 2017]

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Matthew J Sheetz
  • Lloyd Paul Aiello
  • Nazila Shahri
  • Matthew D Davis
  • Keri A Kles
  • Ronald P Danis
  • Mbdv Study Group
View graph of relations
The PKC-DRS2 was a Phase 3, randomized, double-masked, placebo (PBO)-controlled, 3-year study of the effect of 32 mg/day of ruboxistaurin (RBX), an orally administered protein kinase C inhibitor, on vision loss in patients with moderate to severe nonproliferative diabetic retinopathy. Ruboxistaurin reduced the occurrence of sustained moderate visual loss (SMVL; ≥15-letter decline in visual acuity sustained for the last 6 months of study participation) from 9.1% in the PBO group (N = 340) to 5.5% in the RBX group (N = 345, P = 0.034). This study evaluates the primary end point of SMVL in a 2-year open-label extension (OLE) of the PKC-DRS2, which began a median of 466 days (range, 263-1,296 days) after the conclusion of PKC-DRS2.
Original languageEnglish
JournalRetina
Volume31
Issue number6
Pages (from-to)1053-9
Number of pages7
ISSN0275-004X
DOIs
Publication statusPublished - 2011

    Research areas

  • Administration, Oral, Diabetic Retinopathy, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Maleimides, Middle Aged, Protein Kinase C, Retreatment, Vision Disorders, Vision Tests, Visual Acuity, Withholding Treatment

ID: 34572754